Research chemicalStimulantResearch chemicalEntactogenSubstituted amphetamine

3-Fluoroethamphetamine (3-FEA)

Also known as 3-FEA · 3-fluoroethamphetamine · 3-fluoro-N-ethylamphetamine

Written by enwyReviewed 4 Aug 20262 sources0 comments

3-Fluoroethamphetamine (3-FEA) is a fluorinated N-ethyl amphetamine, structurally related to the fluoroamphetamines and fluoroethamphetamine series. It is reported as a stimulant with mild entactogenic character. Human data is essentially absent, making it one of the least-characterised compounds in this set.

01 Overview

3-FEA is the meta-fluoro, N-ethyl homologue in the fluoroamphetamine/ethamphetamine family, related to 3-FA and the 2-FMA series of designer stimulants. The N-ethyl group and fluorine position combine to produce a stimulant with some serotonergic, mildly entactogenic character.

There is virtually no scientific or medical literature specific to 3-FEA; understanding is extrapolated from its structural relatives. Effective doses, safety and neurotoxicity are unknown, and it should be treated as an essentially uncharacterised novel stimulant.

02 Mechanism

Presumed to act as a releasing agent and reuptake inhibitor of dopamine, noradrenaline and serotonin, by analogy with related fluorinated amphetamines; exact profile is unconfirmed.

03 Dosing

Tier	Dose	Route	Notes
Light	20–40 mg	Oral	Anecdotal only; extrapolated from related compounds.
Common	20–50 mg	Insufflated	Faster onset; increases redosing and cardiovascular risk.
Common	40–80 mg	Oral	Highly uncertain; no reliable dosing data exists.

04 Effects

Effect	Magnitude	Evidence
StimulationEnergy and wakefulness typical of substituted amphetamines.	moderate	Anecdotal
Mild entactogenic mood liftSome empathogenic warmth reported, weaker than MDMA-class entactogens.		Anecdotal
Appetite suppressionReduced hunger during the active period.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Unknown neurotoxicitySerotonergic amphetamines can be neurotoxic; 3-FEA's profile is untested, so risk is unquantified.	Moderate	Unknown	Unconfirmed
Comedown and compulsive redosingFatigue and low mood after use, with reinforcement driving redosing.	Moderate	Common	Anecdotal
Cardiovascular strainTachycardia and hypertension expected from its class; specific data absent.	Severe	Common	Unconfirmed

06 Legal status

Psychoactive Substances Act 2016

Production and supply prohibited. · as of Jan 2026

United States

Not federally scheduled by name

Possible analogue under the Federal Analogue Act. · as of Jan 2026

07 References

Fluorinated amphetamine analogues: emerging NPSEUDA (European Union Drugs Agency)

Substituted amphetamine research chemicalsPubMed

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.